PreveCeutical - Word Origin Preve(ntive) + (Pharma)Ceutical.
“Preve”ntive [pri-ven-tiv] (noun), a medicine or other treatment designed to stop disease or ill health from occurring; “Ceutical” [soo-ti-kuh] (suffix), refined healing item or therapy.
Head quartered in Vancouver, British Columbia, PreveCeutical Medical Inc. has a world class team with a passion for researching and developing innovative solutions for unmet clinical needs. Bringing to market treatments and therapies that make real, palpable differences in the lives of those who need them. The company is staking out important positions in diverse areas such as diabetes and obesity, pain management, neurological disorders and cancer.
Sol-Gel Delivery Platform for Nose-to-Brain Delivery of Therapeutic Compounds
Developing what we believe to be the first FDA approved, a CBD-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. Our proprietary nasal formulations will also be designed to be universally-patient friendly, meaning formulations that can be used in children and adults alike.
Sol-gels are taken via nasal (systemic) administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This effectively bypasses the stomach and intestines - eliminating first pass metabolism - and may dramatically improve bioavailability - even compared to nasal sprays and other newer delivery systems. Additionally, the gel stays in the nasal passages, slowly releasing the CBD while keeping it active for up to seven days. The ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.
We expect to have our delivery platform fully tested, approved and ready for market deployment with licensed medical marijuana company partners in approximately 18 months.
Nature Identical Peptides from the Caribbean Blue Scorpion Venom to Assist with Cancer-Targeted Treatment
We plan to identify active peptides that are providing the immune boosting, pain relieving, and tumour selective properties, then test what happens when used on various abnormal cells like brain, lung and breast cancers.
A preclinical research and development program is now underway. It was designed and is being directed by our Chief Science Officer, Dr. Mak Jawadekar, PhD.
PreveCeutical, and partner Uniquest, are currently screening peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where there exists unmet clinical need, such as cancer. There are numerous research papers in the public domain which show the anecdotal findings and efficacy of venom peptides taken through the proven route of administration on cancerous cells/tumours. Our initial focus will be on targeting a very aggressive form of brain cancer (glioma). From there we plan to extend the program to screen our library of nature identical peptides in a high throughput screening (HTS) manner across a range of other cancers.
Dual Gene Therapy
Dual Gene Therapy Targeting Both Diabetes and Obesity
PreveCeutical’s advantage is demonstrated proof of concept. Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in both diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
“With diabetes, over-production of a particular protein molecule has been identified and purposed to be responsible for the key drivers of diabetes and obesity, starting patient on an inevitable journey of significant co-morbidity and increased rates of mortality.
PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels; this would in turn help our cells to absorb glucose, thus reducing blood sugar levels and prevent the body from storing excessive fat from our diet. Thus gene-silencing does not represent a mere management for diabetes and obesity, it represents the potential for a bona fide cure or, in cases where patients have a pre-disposition to diabetes or are in the pre-diabetes state, it can be applied as a ‘PreveCeutical’ to halt progress to the full-blown disease.
This is not merely theoretical. Five years of painstaking work has gone into this initiative and management has already taken this research through the proof-of-concept stage in cellular models of diabetes and obesity.” – Chief Research Officer: Dr. Harry Parekh, PhD, MRPharmS
PreveCeutical Medical Inc., and partner UniQuest Pty Ltd have signed a research and option agreement proposing to expand the use of their disulphide linker technology to develop non-addictive analgesics for moderate-to-severe pain.
This Research and Development program, led by Dr. Harry Parekh in-conjunction with his fellow collaborators at The University of Queensland’s School of Pharmacy, involves peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment and efficacy determinations in appropriate animal models of pain and inflammation, and may encompass either party’s intellectual property and product line and other pharmaceutical offerings that may fall within the peptide Research and Development program.
Dr. Parekh commented “This is a very exciting and important program as we focus on engineering a novel class of drugs derived from our very own endogenous pain pathways, for example when pain and inflammatory insults occur. Our preliminary work has highlighted that by using our proprietary linker technology we can enhance stability while maintaining, and in some cases enhancing the potency of lead bioactives. Having PreveCeutical on board will accelerate our current program, allowing us to rapidly expand and screen the bioactive library, taking the most promising candidates through to efficacy and pharmacokinetic evaluation.
Peptides are currently being used to target an array of disease indications including metabolic disorders, pain, cancers, cardiovascular and infectious diseases. The therapeutic peptide market is projected to undergo considerable expansion in the foreseeable future as technologies to enhance their stability and bioavailability emerge.
Australia & Canada
Stephen Van Deventer
CHAIRMAN & CHIEF EXECUTIVE OFFICER (CANADA & AUSTRALIA)
Mr. Van Deventer is an experienced business person and corporate director. Specializing in international corporate relations and business development over the last twenty-five years, Mr. Van Deventer has focused on launching small to medium-sized companies into the public markets in Canada, the United States and Europe. He spearheaded the financing and RTO of Aurora Cannabis, after helping to create its structure and provide strategic direction. In addition, raised financing for Hempco, one of the world’s largest industrial producers of hemp and hemp products, and coordinated Aurora's strategic investment in Hempco.
Mak Jawadekar Ph.D.
PRESIDENT & CHIEF SCIENCE OFFICER (CANADA)
Mr. Sutherland, over the last three decades, has overseen hundreds of millions of investor dollars and built start-ups on three continents. One of a rare few who has hands-on experience in developing a successful cannabis company, passing more than 50 inspections by Health Canada. The founding COO for Bedrocan Canada he delivered over $750 Million in returns for shareholders. Mr. Sutherland also managed the first legal transfer of live cannabis plant material from Holland to Canada, as well as the “greenfield” construction and commissioning of Bedrocan’s 52,000 ft2 state-of-the-art automated facility. As the former Investment Commissioner, for the Australian Trade Commission, Mr. Sutherland was responsible for establishing 17 offshore companies entering North America for the first time and guiding $100 million in direct investment and acquisitions between Australian and Canadian companies.
Shabira Rajan MBA, CPA, CGA
CHIEF FINANCIAL OFFICER, CONTROLLER (CANADA) & DIRECTOR (AUSTRALIA)
Ms. Rajan is a senior financial executive with over 20 years of experience, leading the financial discipline for successful businesses in both private and public sectors. Ms. Rajan has a track record of providing leadership for strategic value creation and continuous improvement, as well as, providing effective direction to organizations on issues relating to corporate governance, financial oversight and risk management. One of her leadership roles was that of Director of Finance at Canada Line Rapid Transit Inc., which planned and constructed a $2 billion rapid transit system in metro-Vancouver, on time and within budget.
Harry Parekh Ph.D., MRPharmS
CHIEF RESEARCH OFFICER (AUSTRALIA)
Mr. Holland is an experienced CEO, advocate and business adviser. He has worked around emerging technologies (from R&D to commercialization and deployment); major project development; corporate reengineering; capital raising; and bringing together the strengths of businesses and governments. Mr. Holland co-founded Jeanes Holland and Associates, which provides services to industry, government and academia around renewable energy and sustainable industry development. He also co-founded the Australian Solar Group – a utility-scale solar power developer. He is experienced in markets across Australia, NZ, Asia, the U.S. and Europe and operation across cultures, time zones and jurisdictions. He currently sits on the Advisory Board of the University of Adelaide’s Centre for Energy Technology.
MARKETING DIRECTOR (CANADA & AUSTRALIA)
Ms. Van Deventer is an entrepreneur with a successful track record of accomplishment that she brings to Asterion. Motivated and determined, she was ranked the third highest grossing female business owner in BC, Canada, in 2009. Ms. Van Deventer is a driving force behind the business and is unwavering in her commitment to bringing awareness of health and disease prevention to people everywhere. Ms. Van Deventer partnered with Mr. Van Deventer in the financing and RTO of Aurora Cannabis as well as the financing for Hempco, one of the world’s largest industrial producers of hemp and hemp products and coordinated Aurora’s strategic investment in Hempco.
EXECUTIVE ASSISTANT & OFFICE MANAGER (CANADA & AUSTRALIA)
Ms. Cole has held Administration Support and trainer roles within the Hospitality Industry for seven years. Ms. Cole has also worked for a Venture Capital company for seven years as an executive assistant and office manager. From bookkeeping to event coordination Ms. Cole’s organisation and fortitude keep operations running smoothly.
FOREIGN LEGAL ADVISOR (CANADA)
Nicole Goncalves-Krysinski, Esq., is an attorney and a partner in her law firm in New York City, New York. She has a J.D. from St. John’s University and B.A. from U.C.L.A. Nicole practices in both state and federal courts handling a broad range of cases including complex bankruptcy matters, matrimonial, and criminal defence litigation. Her areas of practice also include contract negotiations, business and transactional law and corporate advisement.